Circassia Pharmaceuticals PLC

Receive alerts
Market Cap:
£67.53 m
52 weeks high
52 weeks low

Viewing results 1-25 of 34


Circassia brings in top Pfizer exec as new chief operating officer

Jonathan Emms, who will officially join in September, arrives at a time when Circassia is transitioning into a more commercially-focused business...

on 12/8/19

Neil Woodford's fall from grace: Where it went wrong for the famed stock-picker

Woodford has made some bad investment calls: Provident Financial, Capita, Circassia Pharmaceuticals and Allied Minds...

on 4/6/19

Circassia Pharmaceuticals study data published in leading medical journal

The ASCENT phase IV study assessed the potential of the company's drug Tudorza to treat moderate-to-very severe chronic obstructive pulmonary disease...

on 8/5/19

Circassia Pharmaceuticals makes strong start to new financial year

The company said first-quarter sales were up 38%. The current trading update was contained in the company's annual results...

on 1/5/19

Circassia on track to achieve underlying profitability in 2020 after recent US approvals

City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”...

on 2/4/19

Circassia gets a double shot in the arm from US regulators

Two of its COPD drugs, Tudorza and Duaklir, have been given the thumbs-up from US regulators...

on 1/4/19

Circassia enters pivotal week with two big FDA decisions due

By Sunday, Circassia will know whether its Duaklir COPD inhaler has been approved for sale in the US and whether Tudorza's supplemental NDA has been given the thumbs-up...

on 25/3/19

Circassia Pharmaceuticals says partner AIT Therapeutics successfully completes FDA pre-submission meeting

The group said AIT anticipates submitting a Premarket Approval application for AirNOvent in the second quarter of 2019 for use in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn...

on 4/2/19

Circassia Pharmaceuticals shares rise as it coughs up US$32mln for PPHN drug

PPHN stands for persistent pulmonary hypertension of the newborn – a condition which affects babies’ lungs and can restrict the amount of oxygen flowing around the body...

on 24/1/19

Circassia Pharmaceuticals upbeat on growth prospects as it guides on revenues and costs

Ahead of a meeting to approve its move to AIM, the speciality pharma, which is focused on respiratory disease, told shareholders it had a healthy cash cushion of £41mln...

on 4/1/19

Peel Hunt spotlights 29 stocks with potential to double on 2-3 year view including Base Resources, Eland O&G, Motif Bio, Circassia

The City broker’s analysts pointed out that December is often a time for winding down and celebrating but with the FTSE All Share looking set to record its worst annual performance since 2008 the festive spirit is a little short this year...

on 18/12/18

Circassia Pharmaceuticals exercises US option over lung disease drug

Circassia said the deal represented an important opportunity both commercially and strategically...

on 11/12/18

Growing opportunities in respiratory space could accelerate Circassia’s path to profitability, says analyst

Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them...

on 9/11/18

AstraZeneca collaboration helps Circassia narrow losses significantly in first half

Circassia promotes AstraZeneca’s Tudorza COPD drug in the US in return for a share of the profits, while it also has the commercial rights to another COPD drug made by AstraZeneca called Duaklir...

on 27/9/18

Woodford will be hoping Sensyne Health can provide some remedy to his flagging funds

The star fund manager has endured a difficult time with his various funds since setting up his own firm in 2014; can Sensyne Health, which joins AIM tomorrow, provide some respite?...

on 16/8/18

Circassia gets March date from FDA to complete review of COPD drug

The FDA will also review a re-labelling of another drug Turdorza for heart conditions associated with COPD...

on 13/8/18

Circassia Pharmaceuticals submits US application for COPD inhaler

The pharma saw a major revolt over its executive pay on Wednesday with more than 20% of shareholders voting against the board’s remuneration...

on 1/6/18

Circassia Pharmaceuticals upbeat as AstraZeneca increases stake

Steve Harris, Circassia’s chief executive, said he expected to see strong revenue growth in 2018 ...

on 24/4/18

Circassia and AstraZeneca to widen scope of COPD inhaler after post-launch trial success

AstraZeneca intends to file for the trial data to be included to widen the marketing label for Turdoza...

on 4/12/17